Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Parmiani

Showing results (111-120 of 301) with videos related to

Pageof 31
Sort By:
Cancer Research|September 15, 1992
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talkM P Colombo, A Modesti, G Parmiani, et al.
FEBS Letters|November 29, 1993
Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNAC Melani, A Silvani, G Parmiani, et al.
Tumori|June 30, 1979
Alien H-2 antigens on a chemically induced fibrosarcoma: further evidence in crude membrane and soluble extracts of the tumorM A Pierotti, S Miotti, G Invernizzi, et al.
Nucleic Acids Research|September 26, 1988
Strain polymorphism and tentative mapping of mouse ornithine decarboxylaseM P Colombo, D Galasso, G Ferrari, et al.
International Journal of Cancer|December 15, 1988
Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burdenF Formelli, C Rossi, M L Sensi, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cellsM Radrizzani, C Gambacorti-Passerini, G Parmiani, et al.
Advances in Pharmacology (San Diego, Calif.)|January 1, 1997
Cytokine gene transduction in the immunotherapy of cancerG Parmiani, M P Colombo, C Melani, et al.
International Journal of Cancer|May 15, 1989
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistanceL Rivoltini, C Gambacorti-Passerini, R Supino, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1988
Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytesD Taramelli, A Mazzocchi, C Clemente, et al.
Immunobiology|August 1, 1983
Expression of H-2 and viral antigens and resistance to the antitumor lysis of tunicamycin-treated MBL-2 lymphoma cellsM P Colombo, M A Pierotti, D Ballinari, et al.
Pageof 31

Showing results (111-120 of 301) with videos related to

Sort By:
Pageof 31
Cancer Research|September 15, 1992
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talkM P Colombo, A Modesti, G Parmiani, et al.
FEBS Letters|November 29, 1993
Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNAC Melani, A Silvani, G Parmiani, et al.
Tumori|June 30, 1979
Alien H-2 antigens on a chemically induced fibrosarcoma: further evidence in crude membrane and soluble extracts of the tumorM A Pierotti, S Miotti, G Invernizzi, et al.
Nucleic Acids Research|September 26, 1988
Strain polymorphism and tentative mapping of mouse ornithine decarboxylaseM P Colombo, D Galasso, G Ferrari, et al.
International Journal of Cancer|December 15, 1988
Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burdenF Formelli, C Rossi, M L Sensi, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cellsM Radrizzani, C Gambacorti-Passerini, G Parmiani, et al.
Advances in Pharmacology (San Diego, Calif.)|January 1, 1997
Cytokine gene transduction in the immunotherapy of cancerG Parmiani, M P Colombo, C Melani, et al.
International Journal of Cancer|May 15, 1989
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistanceL Rivoltini, C Gambacorti-Passerini, R Supino, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1988
Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytesD Taramelli, A Mazzocchi, C Clemente, et al.
Immunobiology|August 1, 1983
Expression of H-2 and viral antigens and resistance to the antitumor lysis of tunicamycin-treated MBL-2 lymphoma cellsM P Colombo, M A Pierotti, D Ballinari, et al.
Pageof 31